Quarterly Result6 May 2026, 04:40 pm
Vimta Labs FY26 Revenue Up 19.5% YoY at ₹4,163 Mn
AI Summary
Vimta Labs Ltd announced its Q4 and FY26 financial results. FY26 revenue reached ₹4,163 Mn, a 19.5% increase YoY. EBITDA margins stood at 35.8%, and PAT margin at 18.6%. Q4 FY26 revenue was ₹1,120 Mn, up 11.5% YoY. The company highlighted strong performance in its Pharma and Food divisions, driven by sustained demand and customer confidence. Vimta Labs sold its Diagnostic and Pathological services business to Thyrocare Technologies, with the transfer completed on October 11, 2024.
Key Highlights
- FY26 revenue increased by 19.5% YoY to ₹4,163 Mn.
- FY26 EBITDA margin was 35.8%, with a PAT margin of 18.6%.
- Q4 FY26 revenue reached ₹1,120 Mn, up 11.5% YoY.
- Q4 FY26 EBITDA was ₹421 Mn, with a margin of 37.6%.
- Basic EPS for FY26 was ₹17.4.